AI for medical documentation is a rapidly growing future market

Smart Reporting successfully closes financing round for 23 million euros

24-Apr-2024 - Smart Reporting has successfully completed a financing round of 23 million euros. TVM Capital Life Science (lead investor) and Bayern Kapital are newly on board in the Series C funding, while the existing investors are also participating in the financing round. The capital raised will primarily ...

Lab Notebook learns to communicate with laboratory devices

labfolder acquires cubuslab and becomes Labforward

23-May-2019 - labfolder GmbH, a electronic laboratory notebook (ELN, Electronic Lab Notebook) provider, and cubuslab GmbH, a provider of a manufacturer-independent platform for the digital integration of laboratory instruments, today announced their merger. The joint company will operate under the name ...

Alternative methods replace animal experiments: 20 years successful work by ZEBET within BfR

ZEBET celebrates its anniversary with an international symposium at BfR in Berlin

28-Oct-2009 - The Centre for Documentation and Evaluation of Alternatives to Animal Experiments (ZEBET) celebrated its 20th birthday with a symposium at the Federal Institute for Risk Assessment (BfR) in Berlin. When it was founded in 1989, ZEBET was the first state research institute in the world with a remit ...

BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility

23-Oct-2009 - BioStorage Technologies, Inc. will expand its European operations with the opening of a new 16,140 square foot (1,499 sq meters) full-service biorepository in Frankfurt, Germany. BioStorage Technologies’ expanded European operations is part of the company’s strategic growth plan to accommodate a ...

curasan to invest approximately 1 million euros in future growth

15-Oct-2009 - curasan AG is to invest in its future growth by implementing a technological investment programme amounting to approximately 1 million euros, despite the current crisis in the financial markets. The aim of the investment package is to significantly strengthen and expand the company’s research, ...

Lonza Group AG and Patheon Inc. Agree to Extend Exclusivity and Due Diligence Period

29-Sep-2009 - The Special Committee of Independent Directors of Patheon Inc. and Lonza Group AG announced the extension until October 15, 2009 of the exclusivity and due diligence period to allow for continued discussions regarding the previously announced non-binding proposal to acquire all of the ...

Cell Biosciences Signs Agreement to Acquire Alpha Innotech

10-Sep-2009 - Cell Biosciences, Inc. and Alpha Innotech Corp. announced that they have entered into a definitive agreement providing for the acquisition of Alpha Innotech by Cell Biosciences for US$1.50per share or approximately US$17.9 millionin cash. This acquisition would significantly expand Cell ...

Lonza Group AG Submits Non-binding Proposal to Acquire All Patheon Inc. Restricted Voting Shares

24-Aug-2009 - The Special Committee of Independent Directors of Patheon Inc. and Lonza Group AG announced that Lonza has submitted a non-binding proposal to acquire all of the outstanding Restricted Voting Shares of Patheon at a price of USD 3.55 per Restricted Voting Share. “Our interest in Patheon is ...

Lonza and LFB Enter Manufacturing Agreement

15-Jul-2009 - Lonza and LFB announced the signing of an agreement to manufacture a monoclonal anti-RhD antibody developed by LFB. Under this agreement, the process developed by LFB will be transferred to Lonza which will provide GMP manufacturing services for supporting the phase III clinical program. Lonza, ...

MorphoSys Achieves Clinical Milestone and Payment in Antibody Alliance

08-May-2009 - MorphoSys AG announced that it has received a milestone payment from its collaboration with Novartis. The payment was triggered by Novartis filing of the necessary documentation to initiate a Phase 1 clinical trial with a HuCAL-derived fully human antibody. This is the second HuCAL antibody to ...